CL2016003306A1 - Comprimidos probióticos bicapa de doble liberación - Google Patents

Comprimidos probióticos bicapa de doble liberación

Info

Publication number
CL2016003306A1
CL2016003306A1 CL2016003306A CL2016003306A CL2016003306A1 CL 2016003306 A1 CL2016003306 A1 CL 2016003306A1 CL 2016003306 A CL2016003306 A CL 2016003306A CL 2016003306 A CL2016003306 A CL 2016003306A CL 2016003306 A1 CL2016003306 A1 CL 2016003306A1
Authority
CL
Chile
Prior art keywords
release
different
probiotic
dual
understand
Prior art date
Application number
CL2016003306A
Other languages
English (en)
Inventor
Timothy Gamble
Anthony Blanch
Original Assignee
Probi Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Usa Inc filed Critical Probi Usa Inc
Publication of CL2016003306A1 publication Critical patent/CL2016003306A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN EN GENERAL SE RELACIONA CON UN SUPLEMENTO DIETÉTICO Y FORMULACIONES FARMACÉUTICAS QUE COMPRENDEN LAS FORMULACIONES DE DOSIFICACIÓN ORAL PROTECTORAS DE ÁCIDO POR CAPAS, QUE COMPRENDEN PROBIÓTICOS Y SE PROPORCIONAN COMO UNIDADES DE FORMA DE DOSIFICACIÓN UNIFICADA Y COHESIVA SIMPLE. CADA CAPA PROTECTORA DE ÁCIDO INDIVIDUAL DE LA FORMA DE DOSIFICACIÓN COHESIVA PROPORCIONA UNO DE UNA CARGA DE PROBIÓTICO DIFERENTE, UN PERFIL DE LIBERACIÓN DIFERENTE PARA LA LIBERACIÓN BLANCO DE PROBIÓTICO A UNA REGIÓN PARTICULAR EN EL TRACTO GASTROINTESTINAL, A AMBAS CARGAS DE PROBIÓTICO DIFERENTES Y PERFILES DE LIBERACIÓN PARA LA LIBERACIÓN BLANCO DE DIFERENTES PROBIÓTICO A REGIONES PARTICULARES EN EL TRACTO GASTROINTESTINAL.</p>
CL2016003306A 2014-07-01 2016-12-22 Comprimidos probióticos bicapa de doble liberación CL2016003306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462019717P 2014-07-01 2014-07-01

Publications (1)

Publication Number Publication Date
CL2016003306A1 true CL2016003306A1 (es) 2017-06-09

Family

ID=55019868

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003306A CL2016003306A1 (es) 2014-07-01 2016-12-22 Comprimidos probióticos bicapa de doble liberación

Country Status (17)

Country Link
US (1) US10799541B2 (es)
EP (1) EP3164145A4 (es)
JP (1) JP2017520577A (es)
KR (1) KR20170021350A (es)
CN (1) CN106535909A (es)
AP (1) AP2016009641A0 (es)
AU (1) AU2015284425B2 (es)
BR (1) BR112016031000B1 (es)
CA (1) CA2951739C (es)
CL (1) CL2016003306A1 (es)
MA (1) MA40071A (es)
MX (1) MX383492B (es)
PH (1) PH12016502463A1 (es)
RU (1) RU2736823C2 (es)
SG (1) SG11201610250WA (es)
WO (1) WO2016003870A1 (es)
ZA (1) ZA201608433B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3048361B1 (fr) * 2016-03-01 2020-12-18 Biose Compositions pour le traitement des candidoses
CN108066296B (zh) * 2016-11-11 2020-11-17 南京益恒寿生命科技有限公司 一种生物学活性组分结肠靶向组合物及其应用
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
PE20210322A1 (es) * 2018-01-05 2021-02-18 Nubiyota Llc Composiciones que comprenden microbiota coseleccionada y metodos para su uso
EP3556226B1 (de) * 2018-04-20 2021-01-20 Raab Vitalfood GmbH Komplex-synbiotikum zum aufbau einer gesunden darmflora
AU2019289515B2 (en) 2018-06-18 2025-07-24 Probi Ab Probiotic compositions and uses thereof
KR102770563B1 (ko) 2018-06-18 2025-02-21 프로비 에이비 락토바실러스 플란타룸 조성물 및 이의 용도
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
WO2020181096A1 (en) * 2019-03-05 2020-09-10 The Texas A&M University System Combinations of tannase and probiotic formulations and methods of use for improving tannin metabolism
GB201905386D0 (en) 2019-04-16 2019-05-29 Probi Ab Probiotic compositions and uses thereof
GB201908154D0 (en) 2019-06-07 2019-07-24 Probi Ab Lactobacillus compositions and uses thereof
GB201908706D0 (en) 2019-06-18 2019-07-31 Probi Ab Lactobacillus compositions and uses thereof
CN110251474B (zh) * 2019-07-15 2022-01-07 北京工商大学 一种淀粉基大肠靶向双层益生菌片的制备方法
CN117159485A (zh) * 2023-08-11 2023-12-05 江中药业股份有限公司 一种益生菌香口丸及其制备方法
WO2026017258A1 (en) 2024-07-18 2026-01-22 Probi Ab Lacticaseibacillus compositions and uses thereof

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037953A (ja) * 1983-08-11 1985-02-27 Herusu Eido:Kk カルシウムを主成分とする栄養補助食品
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ATE214597T1 (de) 1997-12-19 2002-04-15 Merck Patent Gmbh Mehrschichttablette enthaltend probiotische mikroorganismen wie z.b. lactobacilli oder bifidobakterien
JP2000302694A (ja) 1999-04-16 2000-10-31 Fuyuki Mitsuyama 医食兼用物質
US6696057B1 (en) 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
US20020044926A1 (en) 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
US20030118547A1 (en) * 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
EP1151673A3 (en) 2000-05-03 2002-01-02 Societe Des Produits Nestle S.A. Confectionery product having a filling
KR20040018319A (ko) 2000-12-18 2004-03-03 프로비오헬쓰 엘엘씨 락토바실러스 카제이 균주 κε01에서 유래된 정장제 화합물
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
EP1228769A1 (de) 2001-02-02 2002-08-07 Jörg-Peter Prof. Schür Symbiontisches Regenerativum
EP1392245A2 (en) 2001-04-05 2004-03-03 Universite Laval Process for making protein delivery matrix and uses thereof
US6627220B2 (en) 2001-07-13 2003-09-30 Scolr, Inc. Tablets containing heat sensitive materials and method for forming thereof
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
EP1429802B1 (en) * 2001-09-28 2012-11-07 TNTGamble, Inc. Delivery system for biological component
US20070098784A1 (en) * 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
EP1344458A1 (en) 2002-03-12 2003-09-17 Société des Produits Nestlé S.A. Probiotic delivery system
US20030175295A1 (en) 2002-03-15 2003-09-18 Richard Ticktin Composition and method for reducing odors from metabolic processes
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
TW200404544A (en) 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
US20050266069A1 (en) 2002-09-06 2005-12-01 Simmons Donald L Stable probiotic microsphere compositions and their methods of preparation
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US7105336B2 (en) 2002-10-07 2006-09-12 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
CA2504610C (en) * 2002-11-12 2012-02-21 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
EP1607087A1 (en) 2003-03-27 2005-12-21 Hisamitsu Pharmaceutical Co., Inc. Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
US7025998B2 (en) 2003-05-30 2006-04-11 Rotta Research Laboratorium S.P.A. Phytoestrogens and probiotic for women's health
DE602004030922D1 (de) 2003-08-21 2011-02-17 Otsuka Pharma Co Ltd Milchsäurebakterien mit mucosa-immunpotenzierungseffekt
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
WO2005074976A1 (en) 2004-02-09 2005-08-18 Transfert Plus Société En Commandite Composition comprising polymeric material and uses thereof
US20050260181A1 (en) 2004-03-05 2005-11-24 Immunopath Profile, Inc. Compositions and methods for tissue repair
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
GB0410785D0 (en) 2004-05-14 2004-06-16 Glycologic Ltd Improved prebiotic
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
DE102004026706A1 (de) 2004-05-28 2005-12-15 Merck Patent Gmbh Orale Darreichungsform enthaltend probiotische Bakterien
US20060062773A1 (en) 2004-09-21 2006-03-23 The Procter & Gamble Company Compositions for maintaining and restoring normal gastrointestinal flora
US20060115465A1 (en) 2004-10-29 2006-06-01 Macfarlane George Treatment of gastrointestinal disorders
JP5576606B2 (ja) 2005-05-18 2014-08-20 ディーエスエム アイピー アセッツ ビー．ブイ． 微生物の腸内投与用組成物
CA2623968C (en) 2005-09-29 2014-12-09 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for stabilising pharmaceutical administration forms comprising microorganisms
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
WO2007070052A2 (en) 2005-12-14 2007-06-21 Oxthera, Inc. Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
US20070184111A1 (en) 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
EP2117354B1 (en) 2006-12-18 2018-08-08 Advanced BioNutrition Corp. A dry food product containing live probiotic
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
WO2009020595A2 (en) * 2007-08-03 2009-02-12 Shaklee Corporation Nutritional supplement system
US20100239682A1 (en) 2007-09-17 2010-09-23 Antoine Andremont Colonic delivery of antimicrobial agents
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20110223248A1 (en) 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
KR20100120169A (ko) 2008-01-24 2010-11-12 네스텍 소시에테아노님 영양 성분을 담고 있는 캡슐 및 이 캡슐로부터 영양액을 전달하는 방법
MX2010011995A (es) 2008-05-01 2010-12-02 Procter & Gamble Metodos y estuches para el tratamiento de condiciones y trastornos inflamatorios del intestino.
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
CN102123604A (zh) * 2008-06-24 2011-07-13 Wm.雷格利Jr.公司 益生菌口香糖的制造方法
CA2737247C (en) 2008-09-15 2016-10-11 Labopharm Inc. Starch-based microparticles for the release of agents disposed therein
AU2009313867A1 (en) * 2008-11-14 2011-06-30 Patheon Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof
GB0900551D0 (en) 2009-01-14 2009-02-11 Horton Richard Ingestible compositions and processes of preparation
SI2381799T1 (sl) 2009-01-27 2018-12-31 Probiotical S.P.A. Probiotični dodatek z okusom čokolade
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
ZA201107285B (en) 2009-03-06 2012-12-27 Delivtx Inc Microencapsulated bioactive agents for oral delivery and methods of the thereof
WO2010105207A1 (en) 2009-03-13 2010-09-16 The Regents Of The University Of California Prebiotic oligosaccharides
US20100330151A1 (en) 2009-06-25 2010-12-30 Mary Elaine Freeland Method of Promoting Gastrointestinal Health Using a Combination of a Probiotic Microorganism and Chocolate
WO2011009848A2 (en) * 2009-07-20 2011-01-27 Bracco Spa Therapeutic use of probiotics
EP2459203B1 (en) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Lactic acid bacteria and bifidobacteria for treating endotoxemia
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
AU2010339573B2 (en) 2009-12-31 2014-08-28 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
KR101143997B1 (ko) 2010-03-04 2012-05-09 한미사이언스 주식회사 유산균 제제 및 5-ｈｔ4 수용체 효능제를 함유하는 경구 투여용 복합 제제 및 이의 제조방법
WO2011130487A1 (en) 2010-04-14 2011-10-20 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CN103221420A (zh) 2010-05-19 2013-07-24 北卡罗莱纳州立大学 用于递送治疗性肽的组合物和方法
US20140154312A1 (en) 2010-09-17 2014-06-05 Monica Gulati Oral targetted drug delivery system
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
JP2014508186A (ja) * 2011-03-17 2014-04-03 プロバイオティカル・ソシエタ・ペル・アチオニ 抗酸化活性を有するプロバイオティクス細菌およびそれらの使用
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
ES2660775T3 (es) 2011-05-16 2018-03-26 Belano Medical Ag Nuevas bacterias del ácido láctico y composiciones que las contienen contra los resfriados bacterianos
CN202427429U (zh) * 2012-01-09 2012-09-12 北京大北农科技集团股份有限公司 一种多层微囊制备设备
US20130295227A1 (en) 2012-05-01 2013-11-07 Robbert H. ter Haar Composition Comprising a Sensitive Ingredient
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
EP3536328B1 (en) * 2013-02-22 2021-10-27 The Regents of The University of California Food or beverage product, or probiotic composition, comprising lactobacillus johnsonii 456
AU2014239883B2 (en) * 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents

Also Published As

Publication number Publication date
CA2951739C (en) 2023-09-19
SG11201610250WA (en) 2017-01-27
EP3164145A1 (en) 2017-05-10
BR112016031000A2 (es) 2017-08-22
RU2017102952A3 (es) 2019-02-01
MA40071A (fr) 2016-01-07
MX2016016773A (es) 2017-06-30
KR20170021350A (ko) 2017-02-27
AU2015284425B2 (en) 2021-04-01
CA2951739A1 (en) 2016-01-07
WO2016003870A1 (en) 2016-01-07
PH12016502463A1 (en) 2017-04-10
US20170100442A1 (en) 2017-04-13
JP2017520577A (ja) 2017-07-27
CN106535909A (zh) 2017-03-22
BR112016031000B1 (pt) 2022-01-25
US10799541B2 (en) 2020-10-13
ZA201608433B (en) 2023-05-31
RU2736823C2 (ru) 2020-11-20
MX383492B (es) 2025-03-04
AP2016009641A0 (en) 2016-12-31
AU2015284425A1 (en) 2017-01-05
RU2017102952A (ru) 2018-08-01
EP3164145A4 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
CL2016003306A1 (es) Comprimidos probióticos bicapa de doble liberación
CO2017012362A2 (es) Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso
GT201300309A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2- pirimidinil]-amino]-n-[5-(4-metil -1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
CL2017001335A1 (es) Cápsulas blandas de calcifediol.
DOP2015000183A (es) Formulaciones farmacéuticas resistentes a la manipulación indebida
MX363000B (es) Composiciones y usos de las mismas para tratar la inflamación.
DOP2016000024A (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
PL3316867T3 (pl) Tabletki o natychmiastowym uwalnianiu zawierające lek i sposoby wytwarzania tabletek
PE20142284A1 (es) Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo
CO7250447A2 (es) Forma de medicamento para liberar los ingredientes activos
CN302339383S (zh) 包装盒（维生素泡c腾片）
CN302297904S (zh) 多路片包装胶囊
CN302252346S (zh) 药盒
CN302437301S (zh) 药片（心形）
CU20130165A7 (es) Liberación modificada de 4-metil-3-[[-4-(3- piridinil)-2-pirimidinil]amino]-n-5-(4- metil-1h-imidazol-1- il)-3- (trifluorometil) fenil] benzamida solubilizada utilizando acidos orgánicos
CN301956899S (zh) 护理床
CN302452497S (zh) 药瓶(2)
CN302452496S (zh) 药瓶(1)
TH156227A (th) ไพริมิดีนซึ่งถูกเติมวงแหวนที่ถูกแทนที่และการใช้ของสารนั้น (Substituted annellated pyrimidines and use thereof)
CN302173659S (zh) 药品包装盒（麦芽片包装盒）
TH1601000441A (th) ยาเม็ดแบนทางเภสัชกรรมซึ่งประกอบรวมด้วยอะเซทิลซาลิคไซลิคแอซิดและ โคลพิโดเกรล
CN302131994S (zh) 包装盒（宝太安叶酸片31）
CN302332322S (zh) 主动发光车道指示标
CN302425485S (zh) 药片（bys）
CN302384548S (zh) 尿槽